FDA on breakthrough therapy requests by therapy area 2019
This statistic displays the share of breakthrough therapy requests to the FDA by therapeutic area, in the United States, as of 2019. As of end-September of that year, 26 percent of requests for breakthrough therapies came from the oncology area. The FDA recommends that submissions for breakthrough therapy designations should be made prior to phase III.
